<DOC>
	<DOCNO>NCT00594880</DOCNO>
	<brief_summary>The objective study compare two different dos Peg-INF-α-2A ( 90 180 ug/wk ) ability maintain viral control initiate 5 week ART ( antiretroviral therapy ) interruption HIV positive , ART-suppressed subject ( viral load &lt; 50 copies/ml ) determine observe percentage viral load measurement &lt; 400 copies/ml two arm 24-week period , correspond Pegasys monotherapy period ( exclusive dual ART/Pegasys 5-week period ) . Primary analysis `` intent treat '' analysis address hypothesis two different dos Peg-INF-α-2A ( 90 180 ug/week ) similarly effective inhibit viral replication .</brief_summary>
	<brief_title>Antiviral Activity Peg-IFN-Alpha-2A Chronic HIV-1 Infection</brief_title>
	<detailed_description>The high toxicity current Anti-Retroviral Therapy ( ART ) regimens driven number study investigate therapeutic approach aim reduce drug exposure maintain beneficial effect immune reconstitution . Preliminary observation HCV/HIV co-infected individual already support antiviral effect Pegylated Interferon-Alpha-2A ( Peg-IFN-Alpha-2A : Pegasys® ) HIV-1 replication ; however , ability Peg-IFN-Alpha-2A ( single agent ) maintain long-term suppression HIV-1 replication patient interrupt ART achieve immune reconstitution remain undetermined . The rationale address two dos Peg-IFN-Alpha-2A ( 180 90 ug/week ) base antiviral activity report dos low incidence adverse event associate dos low approve HCV therapy ( 90 versus 180ug/week ) . The long-range goal proposal determine Peg-IFN-Alpha-2A monotherapy sustain HIV-1 suppression absence ART infect individual . Our short-range goal determine safety , viral suppressive potential immune correlate Peg-IFN-Alpha-2A administer upon cessation suppressive ART . Based current literature preliminary study , hypothesize weekly dos 90 180 ug/wk Peg-IFN-Alpha-2A administer pharmacologically-suppressed HIV-infected individual course antiretroviral therapy ( ART ) discontinuation result equivalent frequency viral control , low dose result measurably low rate intensity therapy-related adverse event ( AE ) . We propose compare two different dos Peg-IFN-Alpha-2A ( 90 180 ug/wk ) simplification step ART , ability maintain viral load suppression initiate 5 week ART interruption HIV-infected , ART-suppressed patient ( VL &lt; 50 copies/ml ) . Briefly , control determine percentage viral load measurement &lt; 400 copies/ml two arm period 24 week , correspond Pegasys monotherapy period ( exclusive dual ART/Pegasys 5-week period ) . A threshold 400 use base know potential blipping ART 50 400 copies/ml clinical consequence sustain suppression thereafter ( JAMA 2005 , 293:817-829 ) . Primary analysis `` intent treat '' analysis address hypothesis two different dos Peg-IFN-Alpha-2A ( 90 180 ug/week ) similarly effective inhibit viral replication . The secondary objective research : 1 . To prospectively evaluate dose-dependent , treatment-associated toxicity , safety tolerability 29 weekly dos Peg-IFN-Alpha-2A 180 ug 90 ug/week ( association ART initial 5 week , follow 24 week Peg-IFN-Alpha-2A absence ART ) . 2 . To determine innate immunity outcomes correlate Peg-IFN-Alpha-2A dose antiviral activity monitor Natural Killer ( NK ) Dendritic cell ( DC ) subset change ability maintain innate immune function ( DC secretory response , NK antiviral cytotoxic response ) 3 . To determine adaptive immunity outcomes correlate Peg-IFN-Alpha-2A dose antiviral activity monitor T-cell subset change ability maintain cell-mediated proliferative cytokine response recall antigen ( anti-HIV-1 gag p55 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Male female , age ≥ 18 &lt; 65 year Able willing provide inform consent . HIV1 infection document licensed enzymelinked immunosorbent assay ( ELISA ) test kit confirm Western Blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test HIV RNA &lt; 75 copies/ml regimen ) 2 Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) 1 nonnucleoside RTI ( NNRTI ) OR b ) 2 NRTIs Protease Inhibitor ( PI ) least 24 week OR c ) 3 NRTIs HIV RNA &lt; 75 copies/ml screen &gt; 6 month ≥ 400 CD4+ T cells/mm3 ( CD4 nadir ≥ 200 cell ) Female subject childbearing potential : negative pregnancy test ( Beta human horionic gonadotropin ( HCG ) ) . Must agree use appropriate contraceptive method ( barrier device diaphragms condom + spermicidal intrauterine device ( IUD ) oral contraceptive ) study . Karnofsky performance scale score 80 % well Willing adhere treatment schedule approve study investigator conjunction patient 's primary provider . Willing abstain immunomodulatory drug study period , exception study drug ( Pegasys® ) . Patient Health Questionnaire ( PHQ ) 2 score &lt; 2 , OR PHQ9 score &lt; 10 , OR PHQ9 score 1014 AND medical provider 's favorable opinion . In either case , score PHQ9 question # 9 ( suicidal ideation ) must 0 . Thyroid stimulate hormone ( TSH ) within normal range , unless accompany thyroid profile consistent normal thyroid function A negative cardiac stress test &gt; 45yrs men/ &gt; 55yrs woman year age year age two add risk factor coronary artery disease [ smoking , hypertension ( BP &gt; 140/90 antihypertensive medication ) , low Hight density lipoprotein ( HDL ) associate cholesterol ( &lt; 40 mg/dL ) , family history premature Coronary heart disease ( CHD ) ( &lt; 55 yr males/ &lt; 65 female ) ] Framingham score &gt; 15 % ( men ) 10 % ( woman ) ) Currently pregnant breast feeding . CD4 cell count &lt; 400 record CD4 nadir &lt; 200 cells/mm3 History immunomodulatory therapy 2 week 6 month prior enrollment , include , limited : IFNAlpha Beta ( recombinant pegylated ) , systemic corticosteroid ; systemic cancer chemotherapy/irradiation ; cyclosporin ; tacrolimus ( FK506 ) ; OKT3 ; Interleukin , include IL2 ; cyclophosphamide ; methotrexate ; IVIG ( gamma globulin ) ; G/MCSF ; hydroxyurea ; thalidomide ; pentoxifylline ; thymopentin ; thymosin ; dithiocarbonate ; polyribonucleoside . Significant coexist medical condition include : Anemia ( Hgb &lt; 9.1 men , &lt; 8.9 woman ) , Neutropenia ( ANC &lt; 1000 ) , Thrombocytopenia ( platelet count &lt; 50K ) , Liver disease ( AST/ALT &gt; 5x , Total Bilirubin &gt; 1.5x upper limit normal , Total Bilirubin &gt; 3x upper limit norm ( ULN ) receive indinavir ) , Renal disease ( creatinine &gt; 2x upper normal limit ) , condition , active drug/alcohol abuse dependence would interfere study compliance . Any history heart attack , myocardial infarction coronary arterial disease ( MI/CAD ) . . Prior history major depression severe psychiatric disorder/condition require treatment and/or hospitalization PHQ9 score &gt; 14 , OR PHQ9 score &gt; 10 14 lack medical provider 's favorable opinion , score PHQ9 answer # 9 ( suicidal ideation ) &gt; 0 . Evidence chronic active Hepatitis B infection ( Surface Antigen HBsAg ) Hepatitis C plymerase chain reaction ( PCR ) positivity screening ( clear HCV entry &gt; 6 month ) . Past evidence medical condition associate chronic liver disease include genetic hemochromatosis , autoimmune hepatitis , alcoholic liver disease , toxin exposure etc . History neutropenia hematological abnormality Type I diabetes mellitus , type II diabetes mellitus control oral agent and/or insulin . Ongoing treatment Isoniazide , Pyrazinamide , Rifabutin , Rifampicin , Diadenosine Ganciclovir , Valganciclovir , Oxymetholone , Thalidomide Theophylline . History autoimmune process include Crohn 's disease , ulcerative colitis , severe psoriasis , rheumatoid arthritis , myositis , hepatitis etc . History major organ transplantation exist functional graft . Active coronary artery disease within 24 week prior study Hemoglobinopathies sickle cell anemia Thalassemia major . Hypersensitivity Pegasys®or component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Peg-IFN-Alpha-2A</keyword>
	<keyword>Viral Suppression</keyword>
	<keyword>ART cessation</keyword>
	<keyword>Immune function</keyword>
	<keyword>Innate Immunity</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Immune-based therapy</keyword>
	<keyword>Treatment interruption</keyword>
</DOC>